Company Overview and News

108
WCS And Edmonton Mixed Sweet Discounts To WTI: Darkest Before Dawn

2018-10-16 seekingalpha - 2
Activism in Canada is largely responsible for transportation constraints such as pipeline bottlenecks, hurting the Canadian economy in ways that Canadians could never imagine.
BTE CVE CRLFF CEI TOT ENB IMO CNI ZPTAF CHAP RRENF SNZYP TDG SN TRP IMO MEG HKRCP BP VET CVE BTE ECR USEG CHPE CP USO IKM CJ GST-A GST-B GST PTOAF WCP SCAZP HUSKF AXAS PTOAD SGY VET SPE TECK HSE AREX TDGCF CP ROSEU REI AMR MEGEF IPCFF TCKRF RRX ROSE PDS PRCYF RZREF HK SPGYF PTORF

38
Natural Gas Futures Gain Ground on Low Inventory Levels

2018-10-15 zacks
The U.S. Energy Department's weekly inventory release showed a natural gas storage injection that fell in line with market expectations. Meanwhile, natural gas prices rallied to their highest levels since January as inventories remain significantly below their five-year average ahead of the upcoming winter.
ECR CKRGZ CNX.WI CHKVP CRK RRL RRS CHKDH CHKVZ RGRLF CHKDG CHKWZ RRC CHKDJ CHKDP RGRYY CHK CHK.WI GPOR

9
ECR / Eclipse Resources Corp. S-4

2018-10-12 sec.gov - 9
S-4 Table of Contents As filed with the Securities and Exchange Commission on October 12, 2018 Registration No. 333-
ECR

48
Natural Gas Jumps to 8-Month High on Low Storage Levels

2018-10-08 zacks - 1
The U.S. Energy Department's weekly inventory release showed a bigger-than-expected increase in natural gas supplies. Despite the stockpile surge, natural gas prices rallied to their highest levels since January as inventories remain significantly below their five-year average ahead of the upcoming winter.
ECR CKRGZ FCN CNX.WI CHKVP CRK COG CVS CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR

1
Independent Bank Group upgraded to strong buy from outperform at Raymond James

2018-10-04 marketwatch
Yesterday, the EVP & CFO of Independent Bank Group (NASDAQ: IBTX), Michelle Hickox, sold shares ...[...]
ECR IBCP IBTX CNCE MKSI INDB

41
Natural Gas Storage Deficit to 5-Year Average Widens Further

2018-09-28 zacks - 1
The U.S. Energy Department's weekly inventory release showed a smaller-than-expected increase in natural gas supplies. The headline beat, which further widened the storage deficit ahead of the upcoming winter, helped the fuel to remain above the psychologically important $3 level.
ECR CKRGZ CQP CNX.WI LNG CHKVP CRK COG CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR GPN

40
Natural Gas Posts Sharp Weekly Gain on Hefty Storage Deficit

2018-09-24 zacks
The U.S. Energy Department's weekly inventory release showed a larger-than-expected increase in natural gas supplies. Despite the headline miss, a hefty storage deficit ahead of the upcoming winter pointed to tightening fundamentals and spurred the fuel’s price, which gained about 7.6% for the week.
ECR CKRGZ CQP LNG CHKVP CRK RDN COG SBOW CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR

 
ECR / Eclipse Resources Corp. FORM 425 (Prospectus)

2018-09-20 sec.gov
Form 425 August 27, 2018: Eclipse Resources Corporation and Blue Ridge Mountain Resources, Inc. Merger Call FILED BY ECLIPSE RESOURCES CORPORATION PURSUANT TO RULE 425 UNDER THE SECURITIES ACT OF 1933
ECR

 
ECR / Eclipse Resources Corp. 425 (Prospectus)

2018-09-19 sec.gov
425 Filed by Eclipse Resources Corporation (Commission File No. 001-36511) Pursuant to Rule 425 under the Securities Act of 1933, as amended <
ECR

34
Blue Ridge Mountain Resources Announces Key Executive Management Appointment

2018-09-19 globenewswire
IRVING, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Blue Ridge Mountain Resources, Inc. (OTCPK: BRMR) (“Blue Ridge” or the “Company”) today is pleased to announce the appointment of Michael Hodges to Senior Vice President of Finance. Michael’s first day with the Company will be September 19, 2018. Effective upon the successful completion of the Company’s proposed merger with Eclipse Resources Corporation (NYSE: ECR) (“Eclipse”), Michael will assume the role of Executive Vice President and Chief Financial Officer of Eclipse from Matthew DeNezza, who is currently serving in such capacity with Eclipse.
ECR CKRGZ BRMR CHKVP SDRPQ CHKDH CHKVZ SD CHKDG CHKWZ SDOCQ CHKDJ REXX CHKDP RXNRP CHK.WI CHK REXXQ SDRXP SDRXQ

40
Natural Gas Supply Deficit Grows but Faces Florence Threat

2018-09-17 zacks
The U.S. Energy Department's weekly inventory release showed a marginally smaller-than-expected increase in natural gas supplies. Despite the headline beat and a growing storage deficit, strong production and the expected power loss from Hurricane Florence weighed on the fuel’s price, which ended flat over the week.
ECR CKRGZ CQP LNG CHKVP CRK COG SBOW CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR

28
E&P 'Bottom Of The Barrel' Club #18-5: Ex-Chapter 11 Company Stats For The First Half Of 2018

2018-09-17 seekingalpha - 3
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ

12
The Zacks Analyst Blog Highlights: Exxon Mobil, Canadian Natural Resources, Suncor Energy, TOTAL and Eni

2018-09-05 zacks
Chicago, IL – September 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Exxon Mobil Corp. (XOM - Free Report) , Canadian Natural Resources Ltd. (CNQ - Free Report) , Suncor Energy Inc. (SU - Free Report) , TOTAL S.
ECR HLX MACK XOM ATH WTW RUSHA SU RUSHB HII CNQ ADVM AMWD SU SOI

10
Oil & Gas Stock Roundup: ExxonMobil's Oil Find, Canadian Natural's Acquisition & More

2018-09-04 zacks
It was a week where oil prices rose back above $70 a barrel for the first time since July but natural gas futures ended flat.
COP ECR BHI CNQ XOM ABM SU SU

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 27890G100